TrialJournal of clinical psychopharmacology2013
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Kimberly R Warren et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.